Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy. (June 2016)

• Record Type: Journal Article
• Authors: Ben-Ami, Eytan; Schachter, Jacob
• Is Part Of: Melanoma management. Volume 3:Number 2(2016)
• Page Start: 137
• Page End: 147
• Publication Date: 2016-06
• Subjects: adjuvant treatment for melanoma -- anti CTLA-4 -- anti PD-1 -- MAPK pathway inhibitors; Melanoma -- Periodicals; 616.99477005
• DOI: 10.2217/mmt-2016-0002
• Languages: English
• ISSNs: 2045-0885

Abstract

The accelerated development in the treatment of metastatic melanoma, both in molecular targeted therapy and immunotherapy, is already starting to impact on adjuvant therapy in stage III melanoma. Following the approval of ipilimumab for adjuvant therapy in melanoma, clinical trials assessing other checkpoint modulators and MAPK pathway inhibitors as adjuvant treatments for melanoma are currently ongoing. As results from these trials mature in the next few years, a change in the landscape of adjuvant treatment for melanoma is expected, resulting in new challenges in treatment decisions such as optimizing patients selection through predictive and prognostic biomarkers, and management of treatment related adverse events, in particular immune related toxicities.